Gilead Sciences to acquire Oxford University biotech spinout MicroBio for $405M

U.S. pharmaceutical giant Gilead Sciences has announced plans to acquire Oxford University biotech spinout company MiroBio in an all-cash deal worth $405 million.
MicroBio is a clinical-stage company focused on developing treatments to “restore immune balance” in autoimmune patients, which is when a person’s immune system attacks their own body tissues. Spearheaded by Professor Simon Davis and Professor Richard Cornall, the company spun out of Oxford University in 2019, and has gone on to raise $130 million in venture funding, including a $97 million tranche back in June from

リンク元